Shares of Lupin today gained over 3 per cent as brokers have upgraded the stock citing higher sales from key drugs.
The shares surged 3.3 per cent adding to Wednesday’s 2.7 per cent rise.
Credit Suisse has upgraded the stock to “outperform’’ from “neutral’’ citing upside from the anti-diabetes generic drugs Fortamet and Glumetza.
Lupin has taken 200 per cent price increase in Fortamet, it said.
Nomura had upgraded Lupin stock to “buy’’ from “neutral’’ on Tuesday.
HSBC had also upgraded the stock to “buy’’ from “hold’’ last week.